Literature DB >> 17984978

A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner.

Arkasubhra Ghosh1, Yongping Yue, Yi Lai, Dongsheng Duan.   

Abstract

The trans-splicing (ts) and overlapping (ov) vectors expand the packaging capacity of adeno-associated virus (AAV). But their application depends on the inherent properties of the target gene. The ts vectors require an optimal gene-splitting site and the ov vectors require a highly recombinogenic domain. In order to overcome these limitations, we developed a hybrid dual (hd) vector system. In the hd vectors, we inserted a highly recombinogenic alkaline phosphatase (AP) sequence in the ts vectors to allow for transgene-independent reconstitution through homologous recombination of the AP sequences. We first tested the hybrid system with the LacZ gene. Both in the cell line (in vitro) and in the mouse muscle (in vivo), the hd vectors significantly outperformed the ts and ov vectors. In muscle, the transduction efficiency of the hybrid vectors reached 80% of that from the single intact vector. Southern blot confirmed AP sequence-mediated transgene reconstitution. In order to validate the hybrid system, we split the 6 kilobase (kb) mini-dystrophin gene at the exon 55/56 junction, a predicted poor site for the ts approach. In dystrophic mdx mouse muscle, the hd vectors yielded 5.6-fold higher transduction than the ts vectors did. Taken together, these data suggest that the hybrid system efficiently expresses large therapeutic genes that are poor candidates for the ts and ov approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984978     DOI: 10.1038/sj.mt.6300322

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  64 in total

1.  Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma.

Authors:  Yadong Zhang; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2011-10-24       Impact factor: 5.695

2.  Recombinant adeno-associated viral vector production and purification.

Authors:  Jin-Hong Shin; Yongping Yue; Dongsheng Duan
Journal:  Methods Mol Biol       Date:  2012

3.  Split AAV-Mediated Gene Therapy Restores Ureagenesis in a Murine Model of Carbamoyl Phosphate Synthetase 1 Deficiency.

Authors:  Matthew Nitzahn; Gabriella Allegri; Suhail Khoja; Brian Truong; Georgios Makris; Johannes Häberle; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2020-04-17       Impact factor: 11.454

Review 4.  Progress in gene therapy of dystrophic heart disease.

Authors:  Y Lai; D Duan
Journal:  Gene Ther       Date:  2012-02-09       Impact factor: 5.250

5.  Full-length dystrophin reconstitution with adeno-associated viral vectors.

Authors:  William Lostal; Kasun Kodippili; Yongping Yue; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2014-03-31       Impact factor: 5.695

6.  AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility.

Authors:  Stephen C Kolwicz; Guy L Odom; Sarah G Nowakowski; Farid Moussavi-Harami; Xiaolan Chen; Hans Reinecke; Stephen D Hauschka; Charles E Murry; Gregory G Mahairas; Michael Regnier
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

7.  Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.

Authors:  Patrice Vidal; Serena Pagliarani; Pasqualina Colella; Helena Costa Verdera; Louisa Jauze; Monika Gjorgjieva; Francesco Puzzo; Solenne Marmier; Fanny Collaud; Marcelo Simon Sola; Severine Charles; Sabrina Lucchiari; Laetitia van Wittenberghe; Alban Vignaud; Bernard Gjata; Isabelle Richard; Pascal Laforet; Edoardo Malfatti; Gilles Mithieux; Fabienne Rajas; Giacomo Pietro Comi; Giuseppe Ronzitti; Federico Mingozzi
Journal:  Mol Ther       Date:  2017-12-28       Impact factor: 11.454

Review 8.  Gene therapy to treat cardiac arrhythmias.

Authors:  Rossana Bongianino; Silvia G Priori
Journal:  Nat Rev Cardiol       Date:  2015-04-28       Impact factor: 32.419

Review 9.  CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.

Authors:  Dan Wang; Feng Zhang; Guangping Gao
Journal:  Cell       Date:  2020-04-02       Impact factor: 41.582

10.  Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb.

Authors:  Yi Lai; Yongping Yue; Dongsheng Duan
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.